Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/24235
Title: Combination studies with gemcitabine in the treatment of non-small-cell lung cancer
Authors: Steward, WP
First Published: 1-Jan-1998
Publisher: Churchill Livingstone
Citation: British Journal Of Cancer, 1998, 78, pp. 15-19
Abstract: Phase II studies have confirmed gemcitabine (GEMZAR) to be an active single agent in treating non-small-cell lung cancer (NSCLC), with response rates averaging 21%. Toxicity, including myelosuppression, is mild, making gemcitabine an attractive agent to consider in combination regimens. Most experience with gemcitabine in combination has been with cisplatin. Five phase II studies have been performed using different scheduling and dosage regimens. Response rates varied from 38% to 54% and median survival was 8.4-14.3 months. This combination was well tolerated and required minimal hospitalization. Haematological toxicity of short duration was dose limiting, with thrombocytopenia WHO grades 3/4 in 16-52% of patients and neutropenia in 36-58%. Nausea and vomiting occurred with cisplatin. Ifosfamide has been combined with gemcitabine in a phase I/II study. Based on phase I data, ifosfamide 1500 mg m(-2)day(-1) was chosen for the phase II study. The overall response rate was 32%. Toxicity was mild and was mainly related to short-lived myelosuppression. In summary, the favourable toxicity profile of single-agent gemcitabine enables its safe combination with other active agents in the treatment of NSCLC. The combination with cisplatin appears particularly encouraging, and a phase III study comparing this combination with standard chemotherapy regimens is planned. The combination of gemcitabine with radiotherapy is also under investigation.
DOI Link: 10.1038/bjc.1998.749
ISSN: 0007-0920
eISSN: 1532-1827
Links: http://hdl.handle.net/2381/24235
http://www.nature.com/bjc/journal/v78/n3s/abs/bjc1998749a.html
Type: Journal Article
Description: The final published version of this article is freely available on the publisher's website, and can be accessed through the links provided.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.